Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

By J. Tol, Miriam Koopman, A. Cats, C. Rodenburg, G. Creemers, J. Schrama, Frans L G Erdkamp, A. Vos, C. V. van Groeningen, Harm A. M. Sinnige and 9 more. New England Journal of Medicine, 2009

1,372 citations recorded by the source corpus.

Subfields: Anthropology, History

View Paper: https://www.semanticscholar.org/paper/3c73ea6a9c982d53cd7e86a1154472dd4c15f5b5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

W. De Roock
A. Bardelli
S. Siena
D. Jonker
F. Di Nicolantonio
A. Sartore-Bianchi
S. Venderbosch
D. Tu

Citations in the corpus

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Until then, all chemotherapy (FOLFOX/FOLFIRI)antibody combinations should be regarded as appropriate, and the decision-making will be a complex surrogate, taking into account many clinical factors, as well as patient preferences (see ‘Treatment strategies’) Anti-EGFR antibodies should not be combine”
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010, background): “G13D-mutated).(19-22) The objective response rate in unselected patients was 10.”
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies (2014, methodology): “A pooled analysis of four phase III studies in first-line treatment of mCRC (CAIRO, CAIRO2, COIN and FOCUS) was performed.”
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. (2010, neutral): “7) 3 (5) PVT absent 9 (9) 6 (67) 4 (44) 13.”
Targeting the cancer kinome through polypharmacology (2010, neutral): “For example, preclinical experiments supported the combination of gefitinib and trastuzumab in breast cancer 56,57 , erlotinib and bevacizumab in renal cell carcinoma 58 , and cetuximab and bevacizumab in colorectal cancer 59 , but all of these failed in clinical trials 58,60,61 .”
Machine learning approaches to drug response prediction: challenges and recent progress (2020, methodology): “Tol et al.(66) also performed a clinical trial for mCRC, using combination of capecitabine, oxaliplatin, and bevacizumab, as the baseline treatment to investigate cetuximab.”